UK Team Using Oxford Nanopore Sequencer to Develop Rapid Urinary Tract Infection Dx | GenomeWeb

NEW YORK (GenomeWeb) – Researchers in the UK are working on a rapid sequencing-based diagnostic test for severe urinary tract infections using Oxford Nanopore Technologies' MinIon platform.

The goal is to develop a test that can identify the pathogen involved and predict its antibiotic susceptibility within six hours of taking a urine sample and at a cost that is "attractive to hospital laboratories," according to Justin O'Grady, a medical microbiologist at the University of East Anglia's Norwich Medical School and one of the project's leaders.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.

Feb
23
Sponsored by
NuGEN

This webinar will discuss a project that sought to understand the parent-of-origin epigenetic mechanisms that regulate seed development in plants, with a particular emphasis on differentiating the maternal or paternal origin of epigenetics marks.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.